Unknown

Dataset Information

0

The Hepatoprotection by Oleanolic Acid Preconditioning: Focusing on PPAR? Activation.


ABSTRACT: Objective:Previous studies have characterized the hepatoprotective and anti-inflammatory properties of oleanolic acid (OA). This study aimed to investigate the molecular mechanisms of OA hepatoprotection in concanavalin A- (ConA-) induced acute liver injury. Materials and Methods:ConA (20?mg/kg) was intravenously injected to induce acute liver injury in Balb/C mice. OA pretreatment (20, 40, and 80?mg/kg) was administered subcutaneously once daily for 3 consecutive days prior to treatment with ConA; 2, 8, and 24?h after ConA injection, the levels of serum liver enzymes and the histopathology of major factors and inflammatory cytokines were determined. Results:OA reduced the release of serum liver enzymes and inflammatory factors and prevented ConA mediated damage to the liver. OA elevated the expression levels of peroxisome proliferator-activated receptor alpha (PPAR?) and decreased the phosphorylation of c-Jun NH2-terminal kinase (JNK). Conclusion:OA exhibits anti-inflammatory properties during ConA-induced acute liver injury by attenuating apoptosis and autophagy through activation of PPAR? and downregulation of JNK signaling.

SUBMITTER: Wang W 

PROVIDER: S-EPMC5901823 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Hepatoprotection by Oleanolic Acid Preconditioning: Focusing on PPAR<i>α</i> Activation.

Wang Wenwen W   Chen Kan K   Xia Yujing Y   Mo Wenhui W   Wang Fan F   Dai Weiqi W   Niu Peiqin P  

PPAR research 20180402


<h4>Objective</h4>Previous studies have characterized the hepatoprotective and anti-inflammatory properties of oleanolic acid (OA). This study aimed to investigate the molecular mechanisms of OA hepatoprotection in concanavalin A- (ConA-) induced acute liver injury.<h4>Materials and methods</h4>ConA (20 mg/kg) was intravenously injected to induce acute liver injury in Balb/C mice. OA pretreatment (20, 40, and 80 mg/kg) was administered subcutaneously once daily for 3 consecutive days prior to tr  ...[more]

Similar Datasets

| S-EPMC8087947 | biostudies-literature
| S-EPMC8705357 | biostudies-literature
| S-EPMC4101680 | biostudies-literature
| S-EPMC3009164 | biostudies-literature
| S-EPMC8361479 | biostudies-literature
| S-EPMC9213889 | biostudies-literature
| S-EPMC3631429 | biostudies-literature
| S-EPMC2190030 | biostudies-other
| S-EPMC1885989 | biostudies-literature
| S-EPMC8757604 | biostudies-literature